Together 4-4 brokerage firms show green signal, share of this company can generate huge earnings

Apart from this, Aurobindo Pharma also has strong investment plans. The company has so far invested Rs 190 crore in the biosimilar segment. The drugmaker's ambitious Rs 2,000-crore penicillin G plant in Andhra Pradesh is also expected to come on stream in FY25, management updated.

New Delhi: Pharmaceutical sector giant Aurobindo Pharma has reported better-than-expected results for the quarter ending March. The company's Q4 net profit of Rs 505.90 crore came in above CNBC TV18's estimate of Rs 497.2 crore. But it was 12.2 percent lower than Rs 576.1 crore in the same quarter last year. This type of situation was seen on the operational front as well. The company's Ebitda margin fell to 15.5 percent. Which is more than the expected 15 percent. But it remained lower than the 16.7 percent expected in the same quarter of the previous financial year.

The company's topline grew by 11.4 percent on a year-on-year basis to Rs 6,472.9 crore. The topline was higher than the estimate of Rs 6,382.2 crore.

Brokerage advice on the stock – Brokerage firm DAM Capital is most bullish on the drugmaker. The plant is seen as a major upside trigger in Fy25 under the PLI scheme. The brokerage firm is positive on the company's strong investments in injectables, biosimilars, vaccines and APIs. On that, DAM Capital believes that a meaningful impact of this investment will be seen in Fy25. With the support of these investment plans, the broking firm has maintained its buy rating for the stock. Its target has been fixed at 809 per share

Nuvama Institutional Equities has adopted a bullish view on the stock given the company's investment plan. It has raised the target price by 17 percent to Rs 700.

Kotak Institutional Equities has rated Add on this stock. He has raised the stock target to Rs 625.

While most brokerages are bullish on the company, Motilal Oswal has given a neutral rating on the stock. He has set a target price of Rs 600 for it.

Elara Capital said it expects the stock valuation to increase by FY24-25. He has given Accumulate rating on this stock. Its target has been fixed at Rs 691.

Disclaimer: The investment advice given here represents the personal views of the experts.